Lanjia Medical Secures Tens of Millions in Series A Funding to Accelerate Domestic Intelligent Airway Management Solutions
In August 2023, Shanghai Lanjia Medical Technology Co., Ltd. announced the successful completion of its Series A financing round, amounting to tens of millions of yuan.The investors are Zhangjiagang Shazhou Sci-Tech Innovation Investment Partnership (Limited Partnership) and Phoenix Technology.。
This round of financing fully demonstrates the high attention paid by professional investment institutions to the opportunities for domestic substitution in the intelligent total airway management tools market, as well as their strong recognition of Lanjia Medical’s management team. The successful completion of this financing round has laid a solid foundation for Lanjia Medical’s next stage of rapid development and ushered in a new chapter.
Shanghai Lanjia Medical Technology Co., Ltd. was established in Shanghai in 2021. Over the past two years, it has grown into a robust integrated enterprise specializing in the R&D, production, and sales of intelligent total airway management tools, earning widespread acclaim from users, clinicians, distributors, and other stakeholders. In 2021, the company’s Shanghai Operations Center was launched to oversee nationwide business operations and management. This center houses an Intelligent Airway Management Tools R&D Center dedicated to hardware development, as well as an AI Laboratory responsible for software development, including image algorithms, big data analytics, and acoustic detection equipment. Also in 2021, its wholly-owned subsidiary, Hunan Zhuojun Medical, was established to handle product design output and manufacturing. In 2023, Suzhou Lanjia was founded, featuring an R&D center and a large-scale production base for airway management tools, further expanding production capacity.
In terms of technology, Shanghai Lanjia Medical Technology Co., Ltd. has established core competencies in vision, acoustics, electronics, image processing algorithms, and software development, while further improving its products to benchmark against mid-to-high-end airway management tools from imported brands. With the completion and commissioning of its Suzhou production base, the company plans to complete registration and mass production of more than ten airway management products between 2023 and 2025, comprehensively meeting the usage needs of different types of users.
Mr. Wang Yizhan, founder of Shanghai Lanjia Medical Technology Co., Ltd., and his sales team have over twenty years of experience in sales and distribution for internationally renowned brands, representing top-tier airway management products. They possess extensive expertise in sales and market management. The company’s technical team also brings more than a decade of R&D experience in visualized airway products. This round of financing will propel Shanghai Lanjia Medical to new heights and accelerate the process of import substitution for domestically produced visualized airway management solutions.
Regarding this financing round, Mr. Wang Yizhan, General Manager of Lanjia Medical, statedWe extend our gratitude to Shazhou Sci-Tech Innovation Fund and Phoenix Technology for their investment and support. They are optimistic about the development prospects of intelligent total airway management tools. Domestically produced intelligent total airway management tools will continuously enhance their comprehensive strength, establish a well-integrated layout encompassing R&D, production, and sales, gradually achieve import substitution, and ultimately become the primary driving products in China’s airway management market. With the increasing number of surgical procedures worldwide and the growing demand for comfortable medical care, airway management has become a critical procedure and requirement in the healthcare sector. Shanghai Lanjia Medical Technology Co., Ltd. has pioneered the launch of the world’s first intelligent airway assessment system. This system boasts multiple competitive advantages, including multi-dimensional data assessment, dedicated AI data acquisition modules, and the application of infrared dot matrix modeling technology, enabling accurate and comprehensive airway assessment and management. This intelligent airway management solution assists physicians in selecting more precise and effective airway management tools, thereby enhancing surgical safety and outcomes, reducing complications, and ensuring patient safety. This round of financing will accelerate Shanghai Lanjia Medical’s product R&D, production capacity expansion, and market outreach, helping the company expedite its goal of becoming a leading enterprise in China’s airway management sector.
As investors in this round of financing, Shazhou Sci-Tech Innovation Fund and Phoenix Technology stated that the domestic airway management tools industry is experiencing continuous growth, with Chinese-made airway management tools achieving certain breakthroughs in research and development. Domestic brands focusing on product innovation, high cost-performance ratios, and high-quality services are seizing development opportunities. Lanjia Medical’s Yuansheng Airway Assessment System integrates multiple technological advantages, featuring proprietary algorithms, independent data acquisition modules, and programming tools that facilitate ease of use for physicians. Furthermore, the company’s founding team has cultivated deep expertise in the field of airway management for many years, possesses extensive channel resources, and brings rich experience in product commercialization. They believe that, with capital support, Shanghai Lanjia Medical Technology Co., Ltd. will accelerate its development, continuously pursuing innovation and excellence. Shazhou Sci-Tech Innovation Fund and Zhangjiagang Phoenix Technology Development Co., Ltd. will also provide comprehensive services in areas such as optimizing corporate development strategies, supporting operational management, and fostering industrial collaboration.
Shanghai Lanjia Medical Technology Co., Ltd. is a medical device R&D and manufacturing enterprise established on May 27, 2021, specializing in the research, development, and sales of full airway management tools. As a provider of intelligent airway management solutions, Lanjia Medical possesses advanced technologies and innovative products.
Currently, the company’s product portfolio encompasses a comprehensive range of visualization products for the entire airway. Furthermore, the company has developed a series of intelligent visualized airway management products, such as an airway assessment system, which has been granted an invention patent and is undergoing in-depth development. These products are widely utilized across multiple departments, including Anesthesiology, Critical Care Medicine, Emergency Medicine, and Respiratory Medicine, thereby meeting the diverse airway management needs across various clinical fields.
The Zhangjiagang Shazhou Sci-Tech Innovation Fund was jointly established by the Zhangjiagang Municipal Science and Technology Bureau and Zhangjiagang Innovation Investment Group. Adopting a direct investment strategy, the fund focuses primarily on emerging industrial chain projects in specialized semiconductors, biopharmaceuticals and high-end medical devices, new energy, and the digital economy. Healthcare and high-end medical devices are among its key areas of interest. By attracting a cohort of high-potential, high-quality projects characterized by advanced industrialization, strong market recognition, and high technological content, the fund aims to inject “fresh vitality” into Zhangjiagang’s industrial development and drive industrial transformation and upgrading.
Phoenix Technology serves as the primary operating entity for the Zhangjiagang Phoenix Science and Technology Entrepreneurship Park. The Phoenix Science and Innovation Park is a national-level technology business incubator, a demonstration base for innovation and entrepreneurship among overseas Chinese in Jiangsu Province, and an innovation and entrepreneurship park for returnees from studying abroad in Suzhou City. The park has independently nurtured two individuals included in the National Talent Program, 19 individuals (or teams) under Jiangsu Province’s “Mass Entrepreneurship and Innovation” Talent Program, and 41 Gusu Leading Talents in Suzhou City. It has successively introduced a large number of high-level scientific and technological talent projects from both domestic and international sources, including Wanzhong Yixin, Xiechang Electronics, Fumiao Technology, Matrix Optoelectronics, Xi Rui En Biology, Baobang Electric, Chengyi Semiconductor, and Liaoyuan Semiconductor.